

# Establishing the new gold standard in bone regeneration

---

Corporate primer

## Our story

---



Kuros Biosciences was born in 2000, formed as a spin-out from the prestigious Swiss Federal Institute of Technology in Zurich. In 2017, Kuros was further strengthened by acquiring Xpand Biotechnology

Combining this expertise with our passion for orthobiologics, we set out with one clear mission: **to eliminate orthopedic non-unions in the spine**



## Our contribution



Today, we boast over 150 years of collective research experience in orthobiologics, with corporate bases in the US, Switzerland and the Netherlands.

Our scientific leaders have spent more than three decades developing breakthrough technologies that instruct the body to form bone in a targeted and controlled fashion



**150**  
Years of research



**400+**  
Patients in RCTs



**125**  
Granted patents



**Six**  
Expert advisors

# Our team



**Joost de Bruijn, PhD**  
Chief Executive Officer

- Founder & CEO of Xpand Biotechnology, Scinus Cell Expansion, RevisiOs and Progentix Orthobiology.
- Head of Bone Tissue Engineering at IsoTis Orthobiologics
- Professor at Queen Mary University of London, UK.
- 28+ years of experience in the field of orthobiologics research, product development and commercialisation.



## Executive management

>80 years pharma, medtech and biotech experience



**Pascal Longlade, MD**  
Chief Medical Officer



**Philippe Saudan, PhD**  
Chief Development Officer



**Michael Grau, MBA**  
Chief Financial Officer



**Alistair Irvine, PhD**  
Chief Business Officer



**Frank-Jan van der Velden, MBA**  
Head of Business Affairs

## Commercial management

≈40 years global spine industry experience




**John Griffin, MBA**  
Head of Commercial Operations



**Charlie Campion, PhD**  
Head of Global Marketing

# On a mission to eliminate non-unions



## MedTech



### Description

**Bone graft substitute (BGS)** with advanced submicron surface topography that directs the body to form bone

### Value

Equivalence to autograft and superiority to other BGS, avoiding negative side-effects of harvesting autograft\*

### Status – commercially available

Commercial sales since June 2018, initial focus on the US market and UK through a network of key opinion leader surgeons, distributors and agents (hybrid model)

## Biotech

### Fibrin-Parathyroid Hormone (Fibrin-PTH)

### Description

**Drug-biologic combination** aimed to deliver targeted and controlled bone formation

### Value

Proven safety and efficacy in two orthopedic Phase 2 trials (~400 patients) and superior handling vs competition

### Status – clinical development

Preparing for a Phase 2a clinical study (Q2 2020)


\* Shown in clinically-relevant preclinical studies. Results from in vivo testing may not be predictive of clinical experience in humans.

Fibrin-PTH (KUR-113) is an investigational drug/biologic combination product candidate. Fibrin-PTH (KUR-113) has been evaluated in animals for use in lumbar interbody fusion. The safety & efficacy of Fibrin-PTH (KUR-113) has not yet been evaluated for spinal fusion in humans.

# MagnetOs

---

MagnetOs, our  
flagship product,  
is a **revolutionary  
bone graft** with  
success in the surface



Unique surface with  
**needle-shaped**  
features that are  
**submicron** in size

3D Animation: <http://kurosbio.com/resources/magnetos-3d-animation-the-science-behind-the-surface/>


# Fibrin-PTH (KUR-113)



Our latest product candidate, Fibrin-PTH (KUR-113), aims to deliver targeted and controlled bone formation

This product candidate functions via the **well-established mechanism of action** of parathyroid hormone – or PTH – and the natural healing matrix fibrin

Unlike BMP-2, Fibrin-PTH (KUR-113) **only affects cells already committed to form bone**



Fibrin-PTH (KUR-113) has been implanted in **~300 patients**, reaching its primary endpoint in two human trials for bone healing

Fibrin-PTH (KUR-113) was demonstrated in animal studies of spinal fusion to be **comparable to rhBMP-2**

**Its excellent flowability** and setting properties make it ideal for open or minimally invasive surgical techniques

3D Animation: <https://kurosbio.com/resources/fibrin-ptb-kur-113-3d-animation/>

# Strategic advisory board

Five opinion-leading US spine surgeons and a professor of orthopedic research who are considered expert within their field but with the focus, mentality and motivation to help shape the future of our organization



**Dr Patel, MD**  
Northwestern, Chicago



**Dr Sandhu, MD**  
Georgetown, DC



**Dr Allen, MD**  
UCSD, San Diego



**Dr Sama, MD**  
HSS, New York



**Dr Poesltra, MD**  
Ortho Northcal, CA



**Prof Walsh, PhD**  
UNSW, Australia

# Why trust Kuros?



## Credibility

There is no other team within this field with our level of orthobiologics expertise



- >80 years MedTech, Biotech, Pharma amongst senior management
- 150 years collective orthobiologics research
- Several start-up successes delivered in this sector by the members of the Kuros team

## Data

Our products work by truly unique mechanisms that will be backed by a high level of clinical evidence



- MagnetOs is the subject of 4 peer-reviewed research publications
- Unlike most other synthetic bone grafts, the performance and safety of MagnetOs will be supported by 10 post-market clinical studies
- Fibrin-PTH has been de-risked by 2x successful Phase II orthopedic trauma clinical trials

## Strategy

Our go-to-market strategy is based on extensive experience in the spine industry



- Targeting based on proprietary market research
- Low risk approach to commercialization using blended sales channel and competitive pricing
- Validated by strategic partnerships with specialist spine distributors

## Advocacy

Kuros have already secured the backing of the biggest names in this therapy area



- 5 of the best-known names in US spinal surgery have put their backing behind Kuros
- Endorsed by pre-eminent professor of orthopedic research
- Long history of use by some of the biggest names in spine surgery in EU

Learn more about Kuros: [www.kurosbio.com](http://www.kurosbio.com)



# Kuros Biosciences

Kuros Biosciences AG is a limited company registered in Switzerland. Registered address: Wagistrasse 25, 8952 Schlieren, Switzerland.  
Register of commerce number CHE-104.785.642.